agilon health, inc.: insider trades · United States · SEC (Form 4)

About agilon health, inc.

agilon health, inc. is a US-based healthcare company listed on the NYSE under the ticker AGL, in the United States. The company was founded in 2016 and is headquartered in Westerville, Ohio. Its core strategy is built around transforming primary care for seniors by enabling independent primary-care physicians and physician groups to operate in a value-based care model, rather than a fee-for-service structure. Through its purpose-built platform and partnerships, agilon provides capital, data, payer relationships, operational support, and contract expertise so that physicians can focus on the long-term health of their Medicare-age patients. The company describes its model as the Total Care Model, which aims to preserve physician independence while giving local practices the tools to manage full-risk or capitated arrangements for older adults. From a business-model perspective, agilon health sits in a specialized and competitive corner of the US healthcare market. It is not a traditional insurer or a pure physician practice management roll-up; instead, it is a value-based enablement platform focused on primary care at scale. Its economic performance depends on winning and retaining physician partners, maintaining favorable relationships with Medicare Advantage payers, and managing medical cost trend with discipline. The company’s footprint is national in ambition, but operationally it expands through selected geographies and local market partnerships rather than blanket coverage across the country. Management continues to frame the opportunity around a large and underpenetrated senior-care market in the United States. Recent developments indicate that agilon is in a demanding transition phase. In its fiscal 2025 results, the company reported revenue of $5.93 billion, down 2% year over year, total members on the platform of 625,000, and a full-year net loss of $391 million. Medical margin turned negative in 2025, reflecting elevated medical cost trends and the impact of market exits. At the same time, management said it had completed actions to improve operating discipline, reduce exposure to downside risk, and right-size the business for a more resilient 2026. In its February 2026 outlook, agilon guided to 2026 adjusted EBITDA roughly around breakeven at the midpoint, signaling a focus on execution rather than aggressive growth. For investors, the key read-through is that agilon health remains a transformation story. The company operates in a structurally attractive segment tied to senior care, Medicare Advantage penetration, and the shift toward value-based reimbursement. However, the investment case is highly sensitive to clinical cost trends, payer contract economics, physician-partner retention, and the company’s ability to convert scale into sustainable margins. In short, agilon offers a compelling strategic theme, but one that still requires proof of durable financial stability and consistent execution.